No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

DnaNUDGE COVID “Bubble Test” First in the United Kingdom Launches

Editor: What To Know

  • The London Symphony Orchestra, which is being supported with regular COVID-19 testing by DnaNudge to enable its return to live performance, has played a key role in validating the new method – with forty of its musicians successfully tested at one time from ‘pooled' individual sputum (phlegm) samples using a single “Orchestra on a Cartridge” test.
  • For the DnaNudge COVID Bubble Test, sputum (phlegm) samples are provided in-store by all individuals in the testing pool – up to ten people at a time – and processed by DnaNudge on-the-spot in a single DnaNudge testing cartridge, using DnaNudge's NudgeBox gold-standard RT-PCR analyzer.
  • Up to ten people in work, friends, family, or other close contact bubbles can be tested at the same time – on the same DnaNudge testing cartridge – scaling to as little as £10 per person, with results delivered in just over an hour.

November 10, 2020

DnaNUDGE has launched the consumer launch of the DnaNudge COVID “Bubble Test” – offering lab-standard, highly-accurate COVID-19 group testing on one cartridge for “bubbles” of up to 10 people who do not have symptoms of coronavirus infection. The breakthrough rapid DnaNudge RT-PCR test is now open for online booking and is available by appointment only from DnaNudge’s flagship store in London’s Covent Garden, and will be available as an at-home, by-post service throughout the UK within weeks. Up to ten people in work, friends, family, or other close contact bubbles can be tested at the same time – on the same DnaNudge testing cartridge – scaling to as little as £10 per person, with results delivered in just over an hour.

DnaNudge notes the new COVID pool testing method has been shown to successfully test up to 40 people at the same time, in some cases. The London Symphony Orchestra, which is being supported with regular COVID-19 testing by DnaNudge to enable its return to live performance, has played a key role in validating the new method – with forty of its musicians successfully tested at one time from ‘pooled’ individual sputum (phlegm) samples using a single “Orchestra on a Cartridge” test. Pool testing individuals for COVID-19 is being seen as a cost-efficient and effective way to significantly increase testing capacity, helping to maximize the number of people who can be tested over a given period while using fewer testing resources. Since the DnaNudge COVID test is a laboratory-standard PCR test, there is no requirement to run a confirmatory test in the event of a positive result. The reason that large numbers can be accurately pooled using the DnaNudge COVID test is because of its direct sample-to-cartridge operation, which suffers less from dilution effects than other sample pooling methods.

DnaNudge is currently rolling out 5.8 million rapid CovidNudge test kits across NHS settings in the UK, provided by DnaNudge to the NHS at cost in support of the national effort to fight the COVID-19 pandemic. By widening access to the DnaNudge rapid test to the general public with very low-cost pool testing options, DnaNudge is continuing its support for the NHS by reducing pressure on community-based testing systems and so ensuring that crucial NHS resources are not used inappropriately. The DnaNudge COVID testing service is available specifically for people without symptoms looking for reassurance about whether they could be infectious – including essential workers – or who require PCR test confirmation of their COVID-19 status before traveling abroad.

The CE-marked DnaNudge COVID test accurately detects the presence of SARS-CoV-2 – the virus that causes COVID-19 – from individual naso-pharyngeal, nasal or saliva swab samples within 90 minutes. For the DnaNudge COVID Bubble Test, sputum (phlegm) samples are provided in-store by all individuals in the testing pool – up to ten people at a time – and processed by DnaNudge on-the-spot in a single DnaNudge testing cartridge, using DnaNudge’s NudgeBox gold-standard RT-PCR analyzer.  For the soon to be launched at-home service, samples will be able to be provided securely by post. If a positive result is detected for the pool, swabs from each individual retained from the initial sample collection are processed to identify the positive case (or cases) within the ‘bubble’. Results are then communicated to individuals via text message, with information on appropriate action in line with government public health guidelines. The sputum testing method has been fully validated against DnaNudge’s proven individual nasal swab test – currently in widespread use in NHS hospitals nationwide – and found to deliver comparable accuracy.

Before attending an in-person testing appointment, customers must confirm that they are not displaying any symptoms of COVID-19 infection, and stringent safety measures to ensure the safety of DnaNudge customers and testing staff are in place throughout the store, including pre-entry temperature testing, rigorous hygiene and cleaning protocols, and appropriate use of PPE at all times.

DnaNudge CEO and co-founder Regius Professor Chris Toumazou comments: “Ever since this global crisis began and the scale of the public health challenges began to be recognized, DnaNudge has worked alongside front-line clinicians and tirelessly diverted our skills and energies into developing this DnaNudge COVID test that, today, is successfully boosting the country’s rapid testing capacity and helping to improve patient and staff safety right across the NHS. By making this transformative test more widely accessible, at very low-cost, our aim is to help improve the detection of asymptomatic yet infectious individuals and to support the huge effort to bring this virus under control and move us all forwards toward safety and a return to normality as soon as we possibly can.”

The DnaNudge COVID test is a rapid, portable, out-of-laboratory RT-PCR (reverse transcription-polymerase chain reaction) test that delivers results on the spot, at the point of need, and in just over an hour. A paper published by the peer-reviewed journal The Lancet Microbe confirms that the test delivers highly accurate results, with an average sensitivity – the ability to correctly identify those with COVID-19 – of 94.4% compared against standard NHS lab-based tests, and a specificity – correctly identifying those without the disease – of 100%, meaning no false positives. The CE-marked CovidNudge solution is now being deployed UK-wide in NHS urgent patient care and elective surgery settings, plus out-of-hospital locations.

Additional notes:

  • The DnaNudge COVID testing service and DnaNudge COVID Bubble Test is specifically for people without symptoms of COVID19. The key symptoms of COVID-19 are any of the following: a new continuous cough, a high temperature, and a loss of, or change in, your normal sense of taste or smell. If you, or anyone in your ‘bubble’, have symptoms of COVID-19, or if you think you may have COVID-19, please stay at home and consult current government guidance.
  • DnaNudge can provide a COVID19 travel certificate to confirm that the virus which causes COVID-19 was not detected and that this result was produced using a RT-PCR method. Please ensure that you check with your airline and destination country that our certificate is appropriate and acceptable before booking the DnaNudge COVID test.
  • For more information about the test and our safety procedures preappointment and in-store, please visit: https://www.dnanudge.com/en/COVIDBubble-test

 

Other Biotechnology News

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Preci and Biopredic International Partner for Higher Performance of Suspended Pooled Hepatocytes with Extended Longevity and Large-scale Availability

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.

The Future of Biotechnology: Insights Into Cutting-Edge Developments

The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.

Advancing Patient Care: LyGenesis Doses First Patient in Phase 2a Trial

"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."

spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy